The Safety and Efficacy of GMDTC for Injection in Subjects With Elevated Cadmium Levels

Inclusion Criteria: Study participants must meet all of the following criteria to be enrolled in this trial: 1. Voluntarily sign the informed consent form, aged between 18 and 70 years (inclusive), regardless of gender; 2. Single morning urine cadmium \>5 μg/g creatinine (with creatinine concentration ≥0.3 g/L and ≤3 g/L); 3. eGFR ≥30 mL/min/1.73 m² (calculated using the CKD-EPI formula). Exclusion Criteria: Participants who meet any of the following criteria will be excluded from this study: 1. Currently suffering from any clinically significant disease that, in the investigator's judgment, poses a safety risk for participation in this clinical trial; 2. Patients with a history of kidney disease requiring hemodialysis; 3. Patients with a history of severe infusion-related allergic reactions, known allergies to three or more substances, or known hypersensitivity to any component of this product (e.g., disodium edetate, mannitol); 4. Previous diagnosis of diabetes with poorly controlled blood glucose; 5. History of conditions predisposing to hypokalemia (e.g., periodic hypokalemia, primary aldosteronism); 6. High-risk uncontrolled arrhythmia within the past 6 months, including: 1\) Resting atrial tachycardia with heart rate \>100 bpm, 2) Significant ventricular arrhythmia (e.g., ventricular tachycardia), 3) High-grade atrioventricular block (e.g., Mobitz type II second-degree or third-degree AV block), 4) NYHA Class IV heart failure, 5) Left ventricular ejection fraction (LVEF) \<50%; 7.Prolonged QT/QTc interval at screening/baseline (QTc: \>450 ms in males, \>470 ms in females) or known family history of long QT syndrome; 8. Use of any medication or supplement (e.g., SGLT2 inhibitors like dapagliflozin, canagliflozin, empagliflozin, etc.; GLUT2 inhibitors like cytochalasin B, phloretin, etc.) within 14 days prior to screening that may interact with the investigational drug; 9. Participation in any other clinical trial involving investigational drugs or medical devices within 3 months prior to screening; 10. Major surgery within 4 weeks before screening or planned surgery during the trial that may affect drug metabolism or safety assessment; 11. Blood donation or significant blood loss (≥200 mL, excluding menstrual bleeding), transfusion, or use of blood products within 1 month prior to screening; 12. Intolerance to venipuncture and/or history of syncope due to blood or needle exposure; 13. Pregnant or lactating women, or participants unwilling to use effective non-pharmacological contraception during the trial; 14. Inability to use contraception for 6 months after trial completion; 15.Inability to comply with dietary restrictions or nutritional guidelines; 16.Alcohol abuse or regular alcohol consumption (\>14 units/week; 1 unit ≈ 200 mL beer \[5%\], 25 mL spirits \[40%\], or 85 mL wine \[12%\]) within 6 months before screening, or unwillingness to abstain from alcohol during the trial; 17. Participants with unstable psychiatric disorders, in the investigator's opinion, who cannot cooperate with the study; 18. Any other condition deemed by the investigator to compromise study compliance or safety.